Repro Med Systems/$KRMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Repro Med Systems
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
Ticker
$KRMD
Sector
Primary listing
Employees
73
Headquarters
Website
KRMD Metrics
BasicAdvanced
$195M
-
-$0.06
0.50
-
Price and volume
Market cap
$195M
Beta
0.5
52-week high
$6.61
52-week low
$1.86
Average daily volume
189K
Financial strength
Current ratio
2.439
Quick ratio
1.88
Long term debt to equity
17.35
Total debt to equity
20.508
Profitability
EBITDA (TTM)
-2.28
Gross margin (TTM)
62.26%
Net profit margin (TTM)
-6.41%
Operating margin (TTM)
-7.23%
Effective tax rate (TTM)
-0.84%
Revenue per employee (TTM)
$560,000
Management effectiveness
Return on assets (TTM)
-6.70%
Return on equity (TTM)
-15.58%
Valuation
Price to revenue (TTM)
4.728
Price to book
11.45
Price to tangible book (TTM)
11.93
Price to free cash flow (TTM)
-393.568
Free cash flow yield (TTM)
-0.25%
Free cash flow per share (TTM)
-0.011
Growth
Revenue change (TTM)
22.23%
Earnings per share change (TTM)
-54.70%
3-year revenue growth (CAGR)
13.81%
3-year earnings per share growth (CAGR)
-32.19%
What the Analysts think about KRMD
Analyst ratings (Buy, Hold, Sell) for Repro Med Systems stock.
KRMD Financial Performance
Revenues and expenses
KRMD Earnings Performance
Company profitability
KRMD News
AllArticlesVideos
KORU Medical Systems Announces CEO Transition
Business Wire·1 week ago
KORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance
Business Wire·1 week ago
KORU Medical Systems Announces 510(k) Submission for Clearance of the FreedomEDGE® System with a Commercialized Oncology Biologic
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Repro Med Systems stock?
Repro Med Systems (KRMD) has a market cap of $195M as of March 22, 2026.
What is the P/E ratio for Repro Med Systems stock?
The price to earnings (P/E) ratio for Repro Med Systems (KRMD) stock is 0 as of March 22, 2026.
Does Repro Med Systems stock pay dividends?
No, Repro Med Systems (KRMD) stock does not pay dividends to its shareholders as of March 22, 2026.
When is the next Repro Med Systems dividend payment date?
Repro Med Systems (KRMD) stock does not pay dividends to its shareholders.
What is the beta indicator for Repro Med Systems?
Repro Med Systems (KRMD) has a beta rating of 0.5. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.